S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation

被引:98
作者
Aslan, Joseph E. [1 ,2 ]
Tormoen, Garth W.
Loren, Cassandra P.
Pang, Jiaqing
McCarty, Owen J. T. [2 ]
机构
[1] Oregon Hlth & Sci Univ, Ctr Hlth & Healing CH13B, Sch Med, Dept Biomed Engn, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Sch Med, Portland, OR 97239 USA
基金
美国国家卫生研究院;
关键词
MAMMALIAN TARGET; CELL MOTILITY; ACTIN CYTOSKELETON; CANCER-THERAPY; RAPAMYCIN MTOR; IN-VIVO; MIGRATION; KINASE; INHIBITOR; PROTEINS;
D O I
10.1182/blood-2011-02-331579
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Platelet activation and thrombus formation are under the control of signaling systems that integrate cellular homeostasis with cytoskeletal dynamics. Here, we identify a role for the ribosome protein S6 kinase (S6K1) and its upstream regulator mTOR in the control of platelet activation and aggregate formation under shear flow. Platelet engagement of fibrinogen initiated a signaling cascade that triggered the activation of S6K1 and Rac1. Fibrinogen-induced S6K1 activation was abolished by inhibitors of Src kinases, but not Rac1 inhibitors, demonstrating that S6K1 acts upstream of Rac1. S6K1 and Rac1 interacted in a protein complex with the Rac1 GEF TIAM1 and colocalized with actin at the platelet lamellipodial edge, suggesting that S6K1 and Rac1 work together to drive platelet spreading. Pharmacologic inhibitors of mTOR and S6K1 blocked Rac1 activation and prevented platelet spreading on fibrinogen, but had no effect on Src or FAK kinase activation. mTOR inhibitors dramatically reduced collagen-induced platelet aggregation and promoted the destabilization of platelet aggregates formed under shear flow conditions. Together, these results reveal novel roles for S6K1 and mTOR in the regulation of Rac1 activity and provide insights into the relationship between the pharmacology of the mTOR system and the molecular mechanisms of platelet activation. (Blood. 2011;118(11):3129-3136)
引用
收藏
页码:3129 / 3136
页数:8
相关论文
共 49 条
[11]   Regulation of thrombin-induced stress fibre formation in Swiss 3T3 cells by the 70-kDa S6 kinase [J].
Crouch, MF .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 233 (01) :193-199
[12]   mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer [J].
Dann, Stephen G. ;
Selvaraj, Anand ;
Thomas, George .
TRENDS IN MOLECULAR MEDICINE, 2007, 13 (06) :252-259
[13]   Thrombus formation in vivo [J].
Furie, B ;
Furie, BC .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3355-3362
[14]   Everolimus: A Proliferation Signal Inhibitor with Clinical Applications in Organ Transplantation, Oncology, and Cardiology [J].
Gabardi, Steven ;
Baroletti, Steven A. .
PHARMACOTHERAPY, 2010, 30 (10) :1044-1056
[15]   Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) [J].
Garcia-Martinez, Juan M. ;
Moran, Jennifer ;
Clarke, Rosemary G. ;
Gray, Alex ;
Cosulich, Sabina C. ;
Chresta, Christine M. ;
Alessi, Dario R. .
BIOCHEMICAL JOURNAL, 2009, 421 :29-42
[16]   Sirolimus inhibits oxidative burst activity in transplant recipients [J].
Gee, I ;
Trull, AK ;
Charman, SC ;
Alexander, GJM .
TRANSPLANTATION, 2003, 76 (12) :1766-1768
[17]   The Pharmacology of mTOR Inhibition [J].
Guertin, David A. ;
Sabatini, David M. .
SCIENCE SIGNALING, 2009, 2 (67) :pe24
[18]   mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways [J].
Gulhati, Pat ;
Bowen, Kanika A. ;
Liu, Jianyu ;
Stevens, Payton D. ;
Rychahou, Piotr G. ;
Chen, Min ;
Lee, Eun Y. ;
Weiss, Heidi L. ;
O'Connor, Kathleen L. ;
Gao, Tianyan ;
Evers, B. Mark .
CANCER RESEARCH, 2011, 71 (09) :3246-3256
[19]  
HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868
[20]   Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways [J].
Han, SW ;
Khuri, FR ;
Roman, J .
CANCER RESEARCH, 2006, 66 (01) :315-323